Research programme: DNA-based monoclonal antibody therapeutics - Inovio Pharmaceuticals

Drug Profile

Research programme: DNA-based monoclonal antibody therapeutics - Inovio Pharmaceuticals

Alternative Names: BEAT-HIV programme

Latest Information Update: 30 Aug 2016

Price : $50

At a glance

  • Originator Inovio Pharmaceuticals
  • Class Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Chikungunya virus infections; HIV infections

Most Recent Events

  • 14 Jul 2016 The Wistar Institute secures $US23 million grant from the National Institutes of Health to finance development of BEAT-HIV programme for HIV-1 Infection (Combination therapy) ,
  • 27 May 2014 Preclinical trials in Chikungunya virus infections in USA before May 2014 (IV)
  • 27 May 2014 Pharmacodynamics data from a preclinical trial in Chikungunya virus infections released by Inovio Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top